Ocular Therapeutix, Inc (OCUL) shareholders
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 31,785,634 | 15.00% | 13G (passive) amendment | Sep 30, 2025 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (9.53%), David Kroin (9.53%) | 20,850,000 | 9.53% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 15,227,768 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Nimish Shah Joint filing with Venrock Healthcare Capital Partners III, L.P. (7.30%), VHCP Co-Investment Holdings III, LLC (7.30%) and 4 more | 12,913,420 | 7.30% | 13G (passive) amendment | Sep 30, 2025 |
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (7.90%) | 12,714,874 | 7.90% | 13G (passive) | Sep 30, 2024 |
| Summer Road LLC | 12,134,357 | 5.70% | 13G (passive) | Dec 4, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (5.13%), David Kroin (5.13%) | 11,234,132 | 5.13% | 13G (passive) | Feb 5, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OCUL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 32,844,043 | 14.96% | $322.53M | +190,279 | 0.01% |
| Deep Track Capital, LP | 19,686,282 | 8.96% | $193.32M | – | 2.81% |
| BlackRock, Inc. | 19,376,555 | 8.82% | $190.28M | +3,243,624 | 0.00% |
| Avoro Capital Advisors LLC | 12,540,000 | 5.71% | $123.14M | +225,000 | 1.11% |
| Summer Road LLC | 12,208,296 | 5.56% | $119.89M | +328,471 | 74.46% |
| VR Adviser, LLC | 10,346,926 | 4.71% | $101.61M | – | 3.08% |
| Vanguard Capital Management LLC | 8,832,595 | 4.02% | $86.74M | +113,556 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 7,623,533 | 3.47% | $74.86M | +1,726,384 | 0.01% |
| Logos Global Management LP | 5,300,000 | 2.41% | $52.05M | +1,450,000 | 2.24% |
| State Street Corp | 5,233,282 | 2.38% | $51.39M | +524,863 | 0.00% |
| Geode Capital Management, LLC | 5,021,092 | 2.29% | $49.32M | +491,907 | 0.00% |
| Point72 Asset Management, L.P. | 3,292,193 | 1.50% | $32.33M | −2,242,792 | 0.04% |
| Dimensional Fund Advisors LP | 2,783,367 | 1.27% | $27.33M | +2,133,611 | 0.00% |
| Deltec Asset Management LLC | 2,476,197 | 1.13% | $24.32M | +135,577 | 3.59% |
| Balyasny Asset Management L.P. | 2,270,707 | 1.03% | $22.30M | −421,915 | 0.03% |
| Octagon Capital Advisors LP | 2,075,000 | 0.94% | $20.38M | −1,091,600 | 1.83% |
| Vanguard Portfolio Management LLC | 1,973,130 | 0.90% | $19.38M | +378,464 | 0.00% |
| Northern Trust Corp | 1,799,426 | 0.82% | $17.67M | +273,800 | 0.00% |
| Goldman Sachs Group Inc | 1,761,754 | 0.80% | $17.30M | +651,388 | 0.00% |
| Nuveen, LLC | 1,697,274 | 0.77% | $16.67M | +1,286,194 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 262 | 207M | 94.4% | 34 / 107 | 79 / 38 | 23M | 22M |
| Q1 2026 | 271 | 207M | 94.3% | 79 / 104 | 59 / 51 | 65M | 38M |
| Q4 2025 | 249 | 192M | 87.2% | 59 / 103 | 61 / 20 | 32M | 28M |
| Q3 2025 | 216 | 188M | 85.8% | 51 / 71 | 59 / 18 | 45M | 14M |
| Q2 2025 | 186 | 157M | 71.7% | 24 / 75 | 48 / 31 | 28M | 9M |
| Q1 2025 | 196 | 138M | 62.7% | 35 / 60 | 57 / 16 | 14M | 9M |
| Q4 2024 | 179 | 134M | 60.9% | 31 / 63 | 36 / 17 | 6M | 12M |
| Q3 2024 | 168 | 140M | 63.8% | 35 / 41 | 49 / 17 | 24M | 16M |
| Q2 2024 | 151 | 144M | 65.7% | 39 / 57 | 26 / 35 | 32M | 14M |
| Q1 2024 | 147 | 126M | 57.5% | 47 / 58 | 24 / 17 | 58M | 6M |
| Q4 2023 | 118 | 75M | 34.0% | 26 / 39 | 29 / 21 | 38M | 4M |
| Q3 2023 | 113 | 40M | 18.4% | 8 / 45 | 29 / 30 | 3M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
189 funds held OCUL in Q2 2026, 37% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of OCUL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 9,716,358 | 4.42% | $87.54M | 0.09% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 6,616,995 | 3.01% | $64.98M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 5,284,839 | 2.41% | $51.90M | 0.06% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 2,688,679 | 1.22% | $24.22M | 0.09% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 2,611,078 | 1.19% | $23.53M | 0.10% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 2,252,224 | 1.03% | $18.40M | 0.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 2,003,277 | 0.91% | $19.67M | 0.02% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,789,197 | 0.81% | $17.57M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,570,555 | 0.72% | $15.42M | 0.10% | Jun 30, 2026 |
| Invesco Pharmaceuticals ETF | 1,489,689 | 0.68% | $12.17M | 2.58% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,484,000 | 0.68% | $14.57M | 0.15% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,432,466 | 0.65% | $14.07M | 0.12% | Jun 30, 2026 |
| Select Pharmaceuticals Portfolio | 1,331,717 | 0.61% | $12.00M | 0.80% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 965,858 | 0.44% | $8.70M | 0.05% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 902,797 | 0.41% | $8.13M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pravin Dugel | See Remarks, Director | 3,270,332 | 1.49% | Aug 26, 2026 |
| Namrata Saroj | Chief Business Officer | 220,522 | 0.10% | Nov 9, 2026 |
| Todd Anderman | Chief Legal Officer | 140,484 | 0.06% | Oct 13, 2026 |
| Peter Kaiser | Chief Development Officer | 254,388 | 0.12% | Oct 6, 2026 |
| Jeffrey S. Heier | Chief Scientific Officer | 307,457 | 0.14% | Oct 6, 2026 |
| Donald Notman | Chief Operating Officer | 366,529 | 0.17% | Sep 2, 2026 |
| Sanjay Nayak | Chief Strategy Officer | 326,898 | 0.15% | Aug 26, 2026 |
| Jason Shand Robins | Chief Financial Officer | 68,097 | 0.03% | Jun 12, 2026 |
| Nadia Waheed | Chief Medical Officer | 300,079 | 0.14% | Jun 5, 2026 |
| David Wayne Robinson | Global CCO | 136,000 | 0.06% | Jan 26, 2026 |
| Steve Lawrence Meyers | Chief Commercial Officer | 217,628 | 0.10% | Jan 6, 2026 |
| Riad Sherif | Director | 28,000 | 0.01% | Nov 10, 2026 |
| Adrienne L. Graves | Director | 64,000 | 0.03% | Jun 12, 2026 |
| Seung Suh Hong | Director | 60,933 | 0.03% | Jun 12, 2026 |
| Leslie J. Williams | Director | 65,433 | 0.03% | Jun 12, 2026 |
| Charles M. Warden | Director | 100,464 | 0.05% | Jun 12, 2026 |
| Richard L. Lindstrom Md | Director | 304,492 | 0.14% | Jun 12, 2026 |
| Merilee Raines | Director | 60,933 | 0.03% | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Riad Sherif Director | Nov 6, 2026 | Award | +28,000 | – | – | 28,000 |
| Namrata Saroj Chief Business Officer | Nov 5, 2026 | Sale(10b5-1 plan) | −35,370 | $6.55 | $231.67K | 220,522 |
| Todd Anderman Chief Legal Officer | Oct 8, 2026 | Sale(10b5-1 plan) | −11,984 | $7.29 | $87.36K | 140,484 |
| Peter Kaiser Chief Development Officer | Oct 2, 2026 | Sale(10b5-1 plan) | −9,990 | $7.05 | $70.43K | 254,388 |
| Jeffrey S. Heier Chief Scientific Officer | Oct 2, 2026 | Sale(10b5-1 plan) | −10,869 | $7.05 | $76.63K | 307,457 |
| Donald Notman Chief Operating Officer | Aug 31, 2026 | Sale | −1,099 | $10.24 | $11.25K | 366,529 |
| Pravin Dugel See Remarks, Director | Aug 25, 2026 | Gift | −50,092 | – | – | 0 |
| Pravin Dugel See Remarks, Director | Aug 25, 2026 | Gift | +50,092 | – | – | 744,903 |
| Jeffrey S. Heier Chief Scientific Officer | Aug 24, 2026 | Sale(10b5-1 plan) | −3,296 | $10.78 | $35.53K | 318,326 |
| Pravin Dugel See Remarks, Director | Aug 24, 2026 | Sale(10b5-1 plan) | −21,649 | $10.77 | $233.16K | 2,525,429 |
| Peter Kaiser Chief Development Officer | Aug 24, 2026 | Sale(10b5-1 plan) | −3,035 | $10.77 | $32.69K | 264,378 |
| Sanjay Nayak Chief Strategy Officer | Aug 24, 2026 | Sale(10b5-1 plan) | −1,897 | $10.78 | $20.45K | 326,898 |
| Pravin Dugel See Remarks, Director | Jun 16, 2026 | Gift | −50,092 | – | – | 2,547,078 |
| Pravin Dugel See Remarks, Director | Jun 16, 2026 | Gift | +50,092 | – | – | 50,092 |
| Jason Shand Robins Chief Financial Officer | Jun 10, 2026 | Award | +15,441 | – | – | 68,097 |
| Merilee Raines Director | Jun 10, 2026 | Award | +14,000 | – | – | 60,933 |
| Charles M. Warden Director | Jun 10, 2026 | Award | +14,000 | – | – | 100,464 |
| Richard L. Lindstrom Md Director | Jun 10, 2026 | Award | +14,000 | – | – | 260,933 |
| Leslie J. Williams Director | Jun 10, 2026 | Award | +14,000 | – | – | 65,433 |
| Adrienne L. Graves Director | Jun 10, 2026 | Award | +14,000 | – | – | 64,000 |
| Seung Suh Hong Director | Jun 10, 2026 | Award | +14,000 | – | – | 60,933 |
| Nadia Waheed Chief Medical Officer | Jun 3, 2026 | Sale(10b5-1 plan) | −14,828 | $8.27 | $122.63K | 300,079 |
| Pravin Dugel See Remarks, Director | May 28, 2026 | Gift | +394,696 | – | – | 694,811 |
| Pravin Dugel See Remarks, Director | May 28, 2026 | Gift | −394,696 | – | – | 0 |
| Sanjay Nayak Chief Strategy Officer | May 26, 2026 | Sale(10b5-1 plan) | −1,858 | $8.20 | $15.24K | 328,795 |
| Pravin Dugel See Remarks, Director | May 26, 2026 | Sale(10b5-1 plan) | −21,156 | $8.20 | $173.48K | 2,597,170 |
| Jeffrey S. Heier Chief Scientific Officer | May 26, 2026 | Sale(10b5-1 plan) | −3,018 | $8.20 | $24.75K | 320,350 |
| Peter Kaiser Chief Development Officer | May 26, 2026 | Sale(10b5-1 plan) | −2,967 | $8.20 | $24.33K | 266,141 |
| Pravin Dugel See Remarks, Director | Apr 9, 2026 | Gift | −394,696 | – | – | 2,618,326 |
| Pravin Dugel See Remarks, Director | Apr 9, 2026 | Gift | +394,696 | – | – | 394,696 |
| Peter Kaiser Chief Development Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −2,810 | $8.28 | $23.27K | 269,108 |
| Sanjay Nayak Chief Strategy Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −1,759 | $8.28 | $14.56K | 330,653 |
| Pravin Dugel See Remarks, Director | Feb 23, 2026 | Sale(10b5-1 plan) | −20,056 | $8.28 | $166.06K | 3,013,022 |
| Jeffrey S. Heier Chief Scientific Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −3,057 | $8.28 | $25.31K | 323,368 |
| Nadia Waheed Chief Medical Officer | Feb 20, 2026 | Sale(10b5-1 plan) | −3,510 | $7.74 | $27.17K | 314,907 |
| Richard L. Lindstrom Md Director | Feb 20, 2026 | Buy | +60,229 | $7.66 | $461.35K | 246,933 |
| Donald Notman Chief Operating Officer | Feb 12, 2026 | Sale | −11,446 | $9.04 | $103.47K | 366,356 |
| Nadia Waheed Chief Medical Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −7,863 | $9.04 | $71.08K | 318,417 |
| Sanjay Nayak Chief Strategy Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −10,348 | $9.04 | $93.55K | 332,412 |
| Pravin Dugel See Remarks, Director | Feb 12, 2026 | Sale(10b5-1 plan) | −124,882 | $9.04 | $1.13M | 3,033,078 |
| Donald Notman Chief Operating Officer | Feb 4, 2026 | Sale | −6,035 | $8.54 | $51.54K | 377,802 |
| Donald Notman Chief Operating Officer | Feb 2, 2026 | Sale | −5,455 | $9.14 | $49.86K | 383,837 |
| David Wayne Robinson Global CCO | Jan 21, 2026 | Award | +136,000 | – | – | 136,000 |
| Namrata Saroj Chief Business Officer | Jan 2, 2026 | Award | +79,112 | – | – | 254,620 |
| Nadia Waheed Chief Medical Officer | Jan 2, 2026 | Award | +79,112 | – | – | 326,280 |
| Todd Anderman Chief Legal Officer | Jan 2, 2026 | Award | +64,900 | – | – | 152,468 |
| Jeffrey S. Heier Chief Scientific Officer | Jan 2, 2026 | Award | +79,112 | – | – | 326,425 |
| Peter Kaiser Chief Development Officer | Jan 2, 2026 | Award | +79,112 | – | – | 271,918 |
| Sanjay Nayak Chief Strategy Officer | Jan 2, 2026 | Award | +64,900 | – | – | 342,760 |
| Donald Notman See Remarks | Jan 2, 2026 | Award | +79,112 | – | – | 389,292 |
| Steve Lawrence Meyers Chief Commercial Officer | Jan 2, 2026 | Award | +64,900 | – | – | 217,628 |
| Pravin Dugel See Remarks, Director | Nov 26, 2025 | Gift | −49,754 | – | – | 0 |
| Pravin Dugel See Remarks, Director | Nov 26, 2025 | Gift | +49,754 | – | – | 300,115 |
| Sanjay Nayak Chief Strategy Officer | Nov 24, 2025 | Sale(10b5-1 plan) | −1,878 | $12.04 | $22.61K | 277,860 |
| Jeffrey S. Heier Chief Scientific Officer | Nov 24, 2025 | Sale(10b5-1 plan) | −3,469 | $12.04 | $41.77K | 245,940 |
| Pravin Dugel See Remarks, Director | Nov 24, 2025 | Sale(10b5-1 plan) | −19,530 | $12.04 | $235.14K | 3,157,960 |
| Peter Kaiser Chief Development Officer | Nov 24, 2025 | Sale(10b5-1 plan) | −3,007 | $12.02 | $36.14K | 191,433 |
| Namrata Saroj Chief Business Officer | Nov 5, 2025 | Sale(10b5-1 plan) | −25,865 | $10.74 | $277.79K | 174,135 |
| Todd Anderman Chief Legal Officer | Oct 8, 2025 | Sale(10b5-1 plan) | −11,132 | $12.34 | $137.37K | 87,568 |
| Jeffrey S. Heier Chief Scientific Officer | Oct 2, 2025 | Sale(10b5-1 plan) | −10,502 | $11.04 | $115.94K | 249,409 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ocular Therapeutix's stock actually held short. Settlement fails (shares not delivered on time) peaked at 98,376 shares on Sep 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Namrata Saroj Officer | Nov 5, 2026 | 35,370 | $231.84K | Nov 5, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Todd Anderman Officer | Oct 8, 2026 | 11,984 | $87.32K | Oct 8, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Peter Kaiser Officer | Oct 2, 2026 | 9,990 | $70.46K | Oct 2, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Jeffrey S. Heier Officer | Oct 2, 2026 | 10,869 | $76.64K | Oct 2, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Donald Notman Officer | Aug 31, 2026 | 1,099 | $11.25K | Aug 31, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Sanjay Nayak Officer | Aug 24, 2026 | 1,897 | $20.45K | Aug 24, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Pravin Dugel Officer | Aug 24, 2026 | 21,649 | $233.19K | Aug 24, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Jeffrey S. Heier Officer | Aug 24, 2026 | 3,296 | $35.53K | Aug 24, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Peter Kaiser Officer | Aug 24, 2026 | 3,035 | $32.70K | Aug 24, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Nadia Waheed Officer | Jun 3, 2026 | 14,828 | $122.65K | Jun 3, 2026 | Restricted stock vesting under a registered plan |
| Jeffrey S. Heier Officer | May 26, 2026 | 3,018 | $24.75K | May 26, 2026 | Restricted stock vesting under a registered plan |
| Pravin Dugel Officer | May 26, 2026 | 21,156 | $173.51K | May 26, 2026 | Restricted stock vesting under a registered plan |
| Sanjay Nayak Officer | May 26, 2026 | 1,858 | $15.24K | May 26, 2026 | Restricted stock vesting under a registered plan |
| Peter Kaiser Officer | May 26, 2026 | 2,967 | $24.33K | May 26, 2026 | Restricted stock vesting under a registered plan |
| Sanjay Nayak Officer | Feb 23, 2026 | 1,759 | $14.56K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
See a number that looks wrong?